Oxylipins formed from polyunsaturated fatty acids (PUFAs) are the main mediators of PUFA
effects in the body. They are formed via cyclooxygenase, lipoxygenase, and cytochrome …

We reviewed available evidence for cardiovascular effects of n-3 polyunsaturated fatty acid
(PUFA) consumption, focusing on long chain (seafood) n-3 PUFA, including their principal …

Numerous benefits have been attributed to dietary long-chain omega-3 polyunsaturated fatty
acids (n-3 LC-PUFAs), including protection against cardiac arrhythmia, triglyceride-lowering …

Recent studies have indicated that arachidonic acid is primarily metabolized by cytochrome
P-450 (CYP) enzymes in the brain, lung, kidney, and peripheral vasculature to 20 …

Considerable research supports cardiovascular benefits of consuming omega-3 PUFA, also
known as (n-3) PUFA, from fish or fish oil. Whether individual long-chain (n-3) PUFA have …

Polyunsaturated fatty acids (PUFA) are oxidized by cytochrome P450 epoxygenases to
PUFA epoxides which function as potent lipid mediators. The major metabolic pathways of …

Epoxyeicosatrienoic acids (EETs), which are synthesized from arachidonic acid by
cytochrome P450 epoxygenases, function primarily as autocrine and paracrine effectors in …

Long chain omega-3 fatty acids (FAs) are effective for reducing plasma triglyceride (TG)
levels. At the pharmaceutical dose, 3.4 g/day, they reduce plasma TG by about 25–50% after …

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) protect against
cardiovascular disease by largely unknown mechanisms. We tested the hypothesis that EPA …

Originally regarded as just membrane constituents and energy storing molecules, lipids are
now recognised as potent signalling molecules that regulate a multitude of cellular …